ALZN
Alzamend Neuro, Inc. NASDAQ Listed Jun 15, 2021$1.43
+8.74%
vs $1.31
Mkt Cap $5.4M
52w Low $0.84
32.1% of range
52w High $2.68
50d MA $1.60
200d MA $1.57
P/E (TTM)
—
EV/EBITDA
—
P/B
0.1x
Debt/Equity
0.0x
ROE
-259.8%
P/FCF
-0.1x
RSI (14)
25.90
ATR (14)
$0.12
Beta
-0.05
50d MA
$1.60
200d MA
$1.57
Avg Volume
126.4K
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
3500 Lenox Road NE · Atlanta, GA 30326 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 22, 2026 | AMC | -0.67 | -0.74 | -10.4% | 1.35 | -3.0% | -6.7% | +5.6% | +0.8% | -2.2% | +2.3% | — |
| Mar 11, 2026 | AMC | -0.53 | -0.58 | -9.4% | 2.18 | -1.4% | -4.1% | -2.4% | +2.9% | -11.4% | +3.2% | — |
| Dec 9, 2025 | AMC | -0.83 | -0.30 | +63.9% | 2.17 | +0.0% | -0.5% | +0.9% | -0.5% | -2.8% | +2.4% | — |
| Sep 10, 2025 | AMC | -3.69 | -1.28 | +65.3% | 2.35 | -2.1% | +2.1% | +0.4% | -2.5% | +11.5% | -4.6% | — |
| Mar 10, 2025 | AMC | -2.61 | -1.71 | +34.5% | 6.38 | +0.9% | -1.6% | -4.0% | +3.0% | -1.9% | +32.2% | — |
| Dec 11, 2024 | AMC | -21.42 | -3.60 | +83.2% | 10.80 | -1.7% | -0.8% | +0.0% | +2.5% | +5.7% | -4.7% | — |
| Sep 11, 2024 | AMC | -2.38 | -11.25 | -372.7% | 18.27 | +0.5% | -0.5% | -4.5% | -5.7% | -7.7% | +3.0% | — |
| Jul 30, 2024 | AMC | -2.75 | -13.35 | -385.5% | 30.60 | +10.6% | +5.0% | -1.4% | -7.4% | -22.1% | -9.8% | — |
| Mar 25, 2024 | AMC | -0.32 | -34.20 | -9999.0% | 90.90 | +4.0% | -1.5% | +2.5% | -2.0% | -12.0% | +3.3% | — |
| Dec 15, 2023 | AMC | -0.67 | 39.60 | +6010.4% | 90.00 | +2.0% | +0.0% | -4.0% | -12.3% | +6.9% | +0.2% | — |
| Sep 13, 2023 | AMC | -47.23 | -53.98 | -14.3% | 306.45 | +1.3% | -1.3% | +7.1% | -6.0% | +6.1% | -3.9% | — |
| Jul 27, 2023 | AMC | -30.36 | -40.48 | -33.3% | 634.32 | -6.4% | +0.8% | -4.3% | +3.5% | -2.1% | -14.2% | — |
| Mar 15, 2023 | AMC | -0.04 | -0.06 | -50.0% | 647.19 | +4.3% | -4.8% | -12.4% | -7.5% | +13.5% | +4.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 22 | Ascendiant Capital | Maintains | Buy → Buy | — | $2.11 | $2.10 | -0.5% | -0.5% | -1.4% | -1.0% | -1.5% | -3.5% |
| Sep 25 | Ascendiant Capital | Maintains | Buy → Buy | — | $2.38 | $2.35 | -1.3% | -0.8% | +2.1% | -2.1% | +0.8% | +2.9% |
| Aug 21 | Ascendiant Capital | Maintains | Buy → Buy | — | $2.26 | $2.26 | +0.0% | +4.0% | +6.0% | -2.8% | +0.8% | +0.8% |
| Mar 17 | Ascendiant Capital | Maintains | Buy → Buy | — | $6.09 | $6.41 | +5.3% | +32.2% | +5.1% | +1.2% | +2.8% | +3.3% |
| Dec 16 | Ascendiant Capital | Maintains | Buy → Buy | — | $10.71 | $10.71 | +0.0% | +2.5% | +5.7% | -4.7% | +1.6% | -11.2% |
| Nov 11 | Ascendiant Capital | Maintains | Buy → Buy | — | $13.41 | $13.50 | +0.7% | +0.7% | +2.0% | -5.2% | +0.7% | -6.8% |
| Apr 12 | Maxim Group | Maintains | Buy → Buy | — | $695.61 | $695.25 | -0.1% | +10.6% | +1.8% | +1.3% | +0.5% | -5.0% |
| Oct 1 | Ascendiant Capital | Maintains | Buy → Buy | — | $4158.00 | $3928.50 | -5.5% | -6.5% | +2.4% | -10.5% | -0.8% | +1.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Aug 26, 2026 | AULT MILTON C III | — | Sell | 2,000 | $1.56 | $3K | — | +2.50% | +1.20% |
| Apr 14, 2026 | AULT MILTON C III | — | Buy | 2,000 | $1.03 | $2K | 2,000 | +2.50% | +1.20% |
| Apr 14, 2026 | AULT MILTON C III | — | Buy | 108,388 | $1.00 | $109K | 116,648 | +2.50% | +1.20% |
| Apr 14, 2026 | AULT MILTON C III | — | Buy | 2,000 | $1.03 | $2K | 2,000 | +2.50% | +1.20% |
| Apr 14, 2026 | AULT MILTON C III | — | Buy | 108,388 | $1.00 | $109K | 116,648 | +2.50% | +1.20% |
8-K · 7.01
! Medium
Alzamend Neuro, Inc. -- 8-K 7.01: Regulation FD Disclosure
Sep 29
8-K · 8.01
!! High
Alzamend Neuro, Inc. -- 8-K 8.01: Material Event / Announcement
Jul 21
8-K
Alzamend Neuro, Inc. -- 8-K Filing
Alzamend Neuro's 8-K filing confirms standard regulatory compliance with Inline XBRL formatting requirements, indicating routine administrative reporting with no material business developments affecting investors.
Apr 17
8-K
Unknown — 8-K Filing
ALZN faces a Nasdaq listing compliance violation and has until September 2026 to regain compliance, creating uncertainty about potential delisting risk and near-term stock volatility.
Mar 20
8-K · 1.01
! Medium
Alzamend Neuro, Inc. -- 8-K 1.01: Equity Issuance
Alzamend Neuro secured a $3.0 million at-the-market equity offering through Ascendiant Capital Markets, allowing flexible share issuance to raise capital.
Mar 6
Institutional (13F) — Top 9
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 36,000 | $66K | New | Dec 2025 |
| 2 | Clearstead Advisors, Llc | 10,000 | $11K | — | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 7,556 | $9K | Added | Jun 2026 |
| 4 | Ubs Group Ag | 4,504 | $5K | Reduced | Mar 2026 |
| 5 | Blackrock, Inc. | 437 | $524 | New | Jun 2026 |
| 6 | Ifg Advisory, Llc | 22 | $26 | New | Jun 2026 |
| 7 | Sbi Securities Co., Ltd. | 22 | $26 | New | Jun 2026 |
| 8 | Caitong International Asset Management Co., Ltd | 3 | $4 | New | Jun 2026 |
| 9 | Harbor Investment Advisory, Llc | 1 | $1 | — | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 24,714 | $50K | Feb 2026 |
| 2 | Fidelity Series Total Market Index Fund | 4,644 | $6K | May 2026 |
| 3 | Blackstone Alternative Multi-Strategy Fund | -100 | $-120 | Jun 2026 |
Valuation
Market Cap
$5.4M
Enterprise Value
-$3.4M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.01x
P/B
0.14x
P/S
—
P/FCF
-0.09x
EV/EBITDA
—
Shares Out
451K
Financials (TTM)
Revenue
$0
Net Income
-$9.1M
EBITDA
-$9.1M
Free Cash Flow
-$6.9M
Op Cash Flow
-$6.6M
EPS Basic
$-11.32
EPS Diluted
$-2.30
EPS Forward
$-2.60
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$4.6M
Total Liab.
$635K
Total Equity
$4.0M
Cash
$3.9M
LT Debt
$0
Book Value/Sh
$9.97
Debt/Equity
0.00x
Current Ratio
6.58
Quick Ratio
6.58
Returns & Growth
ROE
-259.8%
ROA
-140.4%
ROIC
-113.3%
Rev Growth YoY
+0.0%
EPS Growth YoY
+91.5%
Price Returns
2W
-28.3%
1M
-22.6%
3M
+13.4%
6M
+31.5%
12M
-46.8%
Technicals
52W High
$2.68
52W Low
$0.84
50d MA
$1.60
200d MA
$1.57
RSI (14)
25.90
ATR (14)
$0.12
Beta
-0.05
Avg Volume
126K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 24, 2026 5:38pm
· Source: financialmodelingprep.com